Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 4Phase EARLY_PHASE1 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Genitourinary 14Gastrointestinal 11CNS 10Thoracic 9Breast 8Gynecologic 7Dermatologic 6Plasma cell 5Sarcoma 4Tumor-Agnostic 2Other hematologic neoplasm 2Other solid neoplasm 1NET 1Head & Neck 1Endocrine 1

Conditions

Advanced Solid Tumor 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Cyclophosphamide 17Carboplatin 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4sintilimab 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Magnetic Resonance Spectroscopy × Other solid neoplasm × Clear all
NCT05599048 2026-05-27

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

University of California, San Francisco

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡